An anonymous director reports

HELIUS MEDICAL TECHNOLOGIES, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF CLASS A COMMON STOCK

Helius Medical Technologies Inc. has arranged an underwritten public offering of its Class A shares. All of the shares of Class A common stock to be sold in the offering will be offered by Helius Medical Technologies. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.

BTIG LLC and Oppenheimer & Co. Inc. are acting as joint bookrunning managers for the offering. Haywood Securities Inc. is acting as a co-manager for the offering. Helius Medical Technologies intends to grant the underwriters a 30-day option to purchase up to an additional 15 per cent of the shares offered in the offering at the public offering price, less the underwriting discounts and commissions.

The offering will only be made by means of written prospectuses and prospectus supplements that form part of Helius Medical Technologies' existing Canadian Multijurisdictional Disclosure System short form base shelf prospectus dated Jan. 26, 2017, in Canada and effective U.S. shelf registration statement on Form S-3 dated Jan. 6, 2017, in the United States. Preliminary prospectus supplements and the accompanying prospectuses will be filed with the securities regulatory authorities in all provinces of Canada, pursuant to the Multijurisdictional Disclosure System, and with the Securities and Exchange Commission (SEC) in the United States. Copies of these documents will be available through the company's profile on the SEDAR website or the SEC's website, as applicable. Alternatively, when available, copies of the preliminary prospectus supplements and the accompanying prospectuses may also be obtained at no cost from BTIG at 825 Third Ave., sixth floor, New York, N.Y., 10022, by telephone at 212-593-7555, or by e-mail to equitycapitalmarkets@btig.com or from Oppenheimer, attention: Syndicate Prospectus Department, 85 Broad St., 26th floor, New York, N.Y., 10004, by telephone at 212-667-8055 or by e-mail at EquityProspectus@opco.com.

The offering is subject to regulatory approval, including approval of the Toronto Stock Exchange.

About Helius Medical Technologies Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The company's first product in development is the portable neuromodulation stimulator.

We seek Safe Harbor.